San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure
• By PharmAsia News
HONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
